Episode Details
Back to Episodes
Cannabis Stocks Surge on Federal Reclassification News: What Schedule III Means for Investors
Published 5 days, 7 hours ago
Description
In the past 48 hours, the cannabis industry has surged on news of imminent US federal reclassification of marijuana from Schedule I to Schedule III, expected as early as April 23, 2026[1][2][5][7]. This Trump administration move, building on a December executive order, acknowledges medical uses, eases research barriers, and could slash crippling Section 280E taxes from 60 to 80 percent, unlocking banking and investment access[2][5][8].
Stocks exploded Wednesday: AdvisorShares Pure US Cannabis ETF (MSOS) jumped 27 percent to over 5 dollars; Curaleaf soared over 30 percent; Tilray Brands (TLRY) rose 14 percent; Canopy Growth (CGC) climbed 21 percent[1][3]. This dwarfs prior muted reactions to rescheduling talks, signaling investor bets on profitability boosts for multi-state operators like Trulieve and Curaleaf[5][7].
No major new deals, partnerships, or product launches emerged in the last 48 hours, though European M&A accelerates with Canadian producers offloading assets amid price compression[6]. Kentucky advanced medical cannabis with two new cultivators ribbon-cut this week[4]. Hemp faced headwinds: US farmers grew 739 million dollars worth in 2025, up 64 percent year-over-year, but pending THC recriminalization looms[4].
Leaders like Tilray are poised for gains via expanded research and pharma-grade products[2][8]. Consumer shifts remain steady, with no fresh price or supply chain data, though reclassification could stabilize markets long plagued by federal-state clashes.
Compared to last week's quiet IRS tip guidance and hemp growth reports, this regulatory pivot marks the biggest catalyst in months, potentially reshaping a fragmented industry into a more investable sector[4]. The National Cannabis Industry Association ramps lobbying May 12 to 14 for broader reform[12]. Volatility persists, as full rules may take 12 to 18 months[1].
(Word count: 298)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Stocks exploded Wednesday: AdvisorShares Pure US Cannabis ETF (MSOS) jumped 27 percent to over 5 dollars; Curaleaf soared over 30 percent; Tilray Brands (TLRY) rose 14 percent; Canopy Growth (CGC) climbed 21 percent[1][3]. This dwarfs prior muted reactions to rescheduling talks, signaling investor bets on profitability boosts for multi-state operators like Trulieve and Curaleaf[5][7].
No major new deals, partnerships, or product launches emerged in the last 48 hours, though European M&A accelerates with Canadian producers offloading assets amid price compression[6]. Kentucky advanced medical cannabis with two new cultivators ribbon-cut this week[4]. Hemp faced headwinds: US farmers grew 739 million dollars worth in 2025, up 64 percent year-over-year, but pending THC recriminalization looms[4].
Leaders like Tilray are poised for gains via expanded research and pharma-grade products[2][8]. Consumer shifts remain steady, with no fresh price or supply chain data, though reclassification could stabilize markets long plagued by federal-state clashes.
Compared to last week's quiet IRS tip guidance and hemp growth reports, this regulatory pivot marks the biggest catalyst in months, potentially reshaping a fragmented industry into a more investable sector[4]. The National Cannabis Industry Association ramps lobbying May 12 to 14 for broader reform[12]. Volatility persists, as full rules may take 12 to 18 months[1].
(Word count: 298)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI